GLP1-SM is a synthetic analog of glucagon-like peptide-1 (GLP-1), utilized in laboratory research to study GLP-1 receptor interactions and associated biochemical pathways. In vitro and preclinical studies explore its effects on glucose regulation mechanisms, insulin-related signaling cascades, and appetite-associated pathways under controlled experimental conditions. Research also examines its role in modulating gastric emptying rates, satiety-related signaling, and metabolic processes relevant to energy regulation models.

Ongoing investigations assess GLP1-SM’s potential applications in metabolic pathway research, obesity-related models, cardiovascular function studies, and neurological process mapping. All work is conducted within laboratory environments for research purposes only.

Important Notice: This product is intended strictly for research purposes only. It is not approved by the FDA and is not intended for human or animal consumption, nor for diagnostic, therapeutic, or clinical applications. Usage of GLP1-SM outside laboratory research settings violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §§ 355(a) and 331(d).

Product Specifications:

• Purity: ≥99% (HPLC verified)
• Formulation: Lyophilized powder
• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Molecular Weight: 4113.6 g/mol
• CAS Number: 910463-68-2
• Synonyms: Semaglutide, NN9535, OG217SC, NNC 0113‑0217, GLP‑1 receptor agonist (GLP‑1RA), long‑acting GLP‑1 analog

Source: PubChem